Printer Friendly

SCHERER ANNOUNCES AGREEMENT WITH GLAXO

 TROY, Mich., June 24 /PRNewswire/ -- R.P. Scherer (NYSE: SHR) announced today that it has recently signed a Development and License Agreement with Glaxo relating to formulations of Glaxo's product, ondansetron (Zofran) in R.P. Scherer's Zydis dosage form. Under the agreement, Glaxo will pay R.P. Scherer to develop a Zydis product and will obtain a license to exclusive worldwide marketing rights.
 Zofran (ondansetron) is a product now widely used to treat nausea and vomiting associated with chemotherapy and radiotherapy. The patented Zydis dosage form technology enables products to be made in a form which dissolves rapidly on the tongue and which does not require water to aid swallowing. It is particularly suitable for patients undergoing chemotherapy and radiotherapy, who may have problems swallowing traditional tablets and capsules.
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The Company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The Company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The Company operates a global network of 15 facilities in 11 countries.
 Glaxo is an integrated research-based group of companies dedicated to the discovery, development, manufacture and marketing of safe and effective medicines. The Glaxo group employs over 45,000 people worldwide.
 Zofran is a registered trademark of Glaxo Group Limited.
 Zydis, Scherersol and Pulsincap are registered trademarks of R.P. Scherer Corporation.
 -0- 6/24/93
 /CONTACT: Nicole Williams, Executive Vice President & CFO, R.P. Scherer Corp., 313-649-0900/
 (SHR)


CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU: LIC

DD -- DE006 -- 5195 06/24/93 09:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:294
Previous Article:BOUSHY PROMOTED TO SENIOR VICE PRESIDENT FOR THE PROMUS COMPANIES
Next Article:CELLEX BIOSCIENCES, INC. ENTERS INTO DISTRIBUTION AGREEMENT WITH TOSOH CORPORATION OF JAPAN
Topics:


Related Articles
R.P. SCHERER ANNOUNCES AGREEMENT TO SELL PACO SUBSIDIARY
R.P. SCHERER SIGNS AGREEMENT WITH PIERRE FABRE
SCHERER HEALTHCARE IN FINANCING AGREEMENT TO ACQUIRE UP TO 60 PERCENT OF MARQUEST MEDICAL PRODUCTS
SCHERER HEALTHCARE ANNOUNCES REVISED AGREEMENT TO ACQUIRE UP TO 65 PERCENT OF MARQUEST MEDICAL PRODUCTS
MARQUEST MEDICAL PRODUCTS ANNOUNCES REVISED AGREEMENT
BIOCHEM PHARMA AND GLAXO EXTEND RESEARCH AGREEMENT
ALAMAR BIOSCIENCES REACHES AGREEMENT IN PRINCIPLE WITH SCHERER HEALTHCARE
R. P. Scherer and Merck Enter Into Global Softgel Development Agreement
Scherer And Glaxo Sign Agreements
Paracelsian Announces Strategic Alliance With R.P. Scherer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters